Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated‐Granulocyte Colony‐Stimulating Factor
Clinical Pharmacology in Drug Development · 2023-08 · 12 (8) · 826-831
DOI: 10.1002/cpdd.1225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 28.01.2023. Verfasst von Naoto Okada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan. Hauptthemen laut MEDLINE: Antibodies, Granulocyte Colony-Stimulating Factor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Polyethylene glycol (PEG) is a polymer covalently attached to proteins to improve their half‐life and efficacy. We previously reported that the PEGylated granulocyte colony‐stimulating factor (PEG‐G‐CSF) is immunogenic, which could adversely impact drug efficacy and safety in animal models. Here, we analyzed the relationship between anti‐PEG antibody titers and the clinical impact of PEG‐G‐CSF in 19 hematological patients. A gradual decrease of anti‐PEG antibody titers from baseline was observed after PEG‐G‐CSF administration. Of the 19 participants, 10 were assessed for noninfectious fever after the first administration of PEG‐G‐CSF and three experienced this reaction. The receiver operating characteristic curve revealed that the cut‐off values of pretreated anti‐PEG IgM and IgG titers for noninfectious fever were set at 5.0 and 96.6 U/mL, respectively. All patients who experienced noninfectious fever had anti‐PEG antibody titers above this cut‐off value ( P = .033). An enzyme‐linked immunosorbent assay revealed that some anti‐PEG antibodies in patients with anti‐PEG antibody titers above the cut‐off value reacted with the PEGylated liposome. These results indicate the reactivity of the anti‐PEG antibodies to PEGylated therapeutics observed in hematologic patients and the possibility of the relationship between high titers of anti‐PEG antibodies and the development of adverse events after PEG‐G‐CSF administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
- Pharmacy Department, Yamaguchi University Hospital, Yamaguchi, Japan.
- Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
- Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
- Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
- Department of Haematology, Endocrinology, and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Zitieren
APA
Okada, N., Taro, S., Ando, H., Nakamura, S., Goda, M., Abe, M., Kitahara, T., Ishida, T., & Ishizawa, K. (2023). Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated‐Granulocyte Colony‐Stimulating Factor. Clinical Pharmacology in Drug Development, 12(8), 826-831. https://doi.org/10.1002/cpdd.1225
Vancouver
Okada N, Taro S, Ando H, Nakamura S, Goda M, Abe M, et al. Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated‐Granulocyte Colony‐Stimulating Factor. Clinical Pharmacology in Drug Development. 2023;12(8):826-831. doi:10.1002/cpdd.1225
BibTeX
@article{Okada2023,
author = {Okada, Naoto and Taro, Shimizu and Ando, Hidenori and Nakamura, Shingen and Goda, Mitsuhiro and Abe, Masahiro and Kitahara, Takashi and Ishida, Tatsuhiro and Ishizawa, Keisuke},
title = {Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated‐Granulocyte Colony‐Stimulating Factor},
journal = {Clinical Pharmacology in Drug Development},
year = {2023},
volume = {12},
number = {8},
pages = {826--831},
doi = {10.1002/cpdd.1225}
}
EUVIMED